|
New data released into Lhasa Carcinogenicity Database
|
|
1
|
635
|
November 17, 2023
|
|
A new root cause? NOx
|
|
13
|
1251
|
November 17, 2023
|
|
Why do some mutagenic N-nitrosamines not require metabolic activation?
|
|
0
|
326
|
November 15, 2023
|
|
Review of NDSRIs in Pharmaceutical Drugs -Pub
|
|
1
|
665
|
November 13, 2023
|
|
Does atmospheric NO2 influence the formation of NDMA in metformin?
|
|
2
|
500
|
November 3, 2023
|
|
Not all Nitro structures are Nitrosamines!
|
|
1
|
686
|
November 2, 2023
|
|
Developing Structure-Activity Relationships for N-Nitrosamine Activity
|
|
7
|
570
|
October 13, 2023
|
|
Nitrosamines in Biologics
|
|
1
|
542
|
September 18, 2023
|
|
Nitrite Detection at Picogram Level, is it possible?
|
|
4
|
845
|
September 14, 2023
|
|
Identifying the Risk of Formation of Nitrosamines and Other Potentially Mutagenic Impurities during API Manufacture Using In Silico Risk Assessment -Pub
|
|
0
|
1042
|
June 6, 2023
|
|
A deep dive into historical Ames study data for N-nitrosamine compounds -Pub
|
|
0
|
348
|
September 8, 2023
|
|
A nitrosamine twist
|
|
0
|
372
|
August 24, 2023
|
|
Strategies for Assessing Acceptable Intakes for Novel N-Nitrosamines Derived from Active Pharmaceutical Ingredients
|
|
4
|
594
|
August 23, 2023
|
|
Approaches and Considerations for the Investigation and Synthesis of N‑Nitrosamine Drug Substance-Related Impurities (NDSRIs)
|
|
0
|
544
|
August 23, 2023
|
|
Maximizing use of existing carcinogenicity data to support AI levels -Pub
|
|
0
|
315
|
July 31, 2023
|
|
Genotoxicity Assessment using HepaRG Models
|
|
2
|
366
|
July 28, 2023
|
|
Forced degradation: predicting nitrosamine formation
|
|
8
|
1281
|
July 20, 2023
|
|
Approaches and Considerations for the Investigation and Synthesis of N-Nitrosamine Drug Substance-Related Impurities (NDSRIs)
|
|
1
|
733
|
May 31, 2023
|
|
Impact of N‑nitrosamines presence and ARB recall on ARB utilization – results from IQVIA™ Disease Analyzer
|
|
1
|
364
|
May 2, 2023
|
|
Nuevas inspecciones en busca de Nitrosaminas y Genotóxicos en API no evaluados
|
|
1
|
551
|
May 1, 2023
|
|
Drawing a line: Where might the cohort of concern end?
|
|
5
|
881
|
April 18, 2023
|
|
N-Nitrosamines and their precursors in wastewater effluents from selected industries in Spain -Pub
|
|
0
|
274
|
March 29, 2023
|
|
Computational Prediction of Metabolic α-Carbon Hydroxylation Potential of N-Nitrosamines: Overcoming Data Limitations for Carcinogenicity Assessment
|
|
5
|
774
|
March 23, 2023
|
|
The Landscape of Small and Drug Substance Related Nitrosamines in Pharmaceuticals
|
|
10
|
1600
|
March 8, 2023
|
|
U̶p̶c̶o̶m̶i̶n̶g̶ Nitrosamine Special Issue of JPS
|
|
3
|
1720
|
March 7, 2023
|
|
Solid State Kinetics of Nitrosation Using Native Sources of Nitrite -Pub
|
|
1
|
792
|
March 6, 2023
|
|
EMA-funded project to predict in-vivo mutagenicity / mutagenicity classification
|
|
6
|
601
|
March 2, 2023
|
|
Current threat of nitrosamines in pharmaceuticals and scientific strategies for risk mitigation -Pub
|
|
0
|
771
|
February 7, 2023
|
|
2 years after pushing FDA to analyze Nitrosamines, Valisure cited it for failing to comply with federal law
|
|
3
|
423
|
February 15, 2023
|
|
Carry over limits for Niitrsoamines
|
|
2
|
614
|
February 12, 2023
|